2 results
Approved WMOCompleted
1. The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to ASA 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism).2.…
Not approvedWill not start
Primary:To evaluate the probability that FNA successfully obtains liver tissue specimens from which to evaluate liver drug concentrationsSecondary:1. To characterize the steady-state hepatic pharmacokinetics of MK-7009 (e.g., area under the liver…